Emergent challenges for CRISPR: biosafety, biosecurity, patenting, and regulatory issues

Abstract The recent advancements of CRISPR-Cas technologies have transformed this simple and efficient gene editing technique into an extraordinarily powerful tool. The most anticipated applications could create novel therapeutics against mankind's most serious afflictions and help eradicate vector-based diseases. However, with these desired benefits come new ethical questions and potential threats. CRISPR technologies are not yet fully developed toward delivering all of their promises, and suffer from biosafety problems in human products and biosecurity threats arising from its potential dual use and errant gene drives. Furthermore, the future innovations of CRISPR technologies may encounter non-scientific challenges in patentability and unclear legal regulations at the national and international levels. This chapter will discuss these issues, and where possible, will highlight the currently proposed solutions that could mitigate the threats, and could address the problems that hold back CRISPR's full potential.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Law, Business, Environmental Science

• Identifiers
  DOI 10.1016/b978-0-12-818140-9.00021-0
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The CRISPR Patent Landscape: Past, Present, and Future

  2018cited by this paper
• CRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development

  2018cited by this paper
• Intracellular generation of single-strand template increases the knock-in efficiency by combining CRISPR/Cas9 with AAV

  2018cited by this paper
• Pivotal CRISPR patent battle won by Broad Institute

  2018cited by this paper
• Erratum: Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements

  2018cited by this paper
• Systematic discovery of natural CRISPR-Cas12a inhibitors

  2018cited by this paper
• CRISPR for Crop Improvement: An Update Review

  2018cited by this paper
• CRISPR-Cas systems: ushering in the new genome editing era

  2018cited by this paper
• p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

  2018cited by this paper
• CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response

  2018cited by this paper
• Cas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editing

  2018cited by this paper
• With a free pass, CRISPR-edited plants reach market in record time

  2018cited by this paper
• Cutting edges and weaving threads in the gene editing (Я)evolution: reconciling scientific progress with legal, ethical, and social concerns

  2018cited by this paper
• Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments

  2018cited by this paper
• A Framework for the Risk Assessment and Management of Gene Drive Technology in Contained Use

  2018cited by this paper
• A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.

  2018cited by this paper
• Safety and Security Risks of CRISPR/Cas9

  2018cited by this paper
• Enabling the Rise of a CRISPR World

  2018cited by this paper
• Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape

  2018cited by this paper
• Assessing Security Implications of Genome Editing: Emerging Points From an International Workshop

  2018cited by this paper
• CRISPR-baby scientist fails to satisfy critics

  2018cited by this paper
• The CRISPR Patent Decision Didn’t Get the Science Right. That Doesn’t Mean It Was Wrong

  2018cited by this paper
• CRISPRminer is a knowledge base for exploring CRISPR-Cas systems in microbe and phage interactions

  2018cited by this paper
• European court ruling raises hurdles for CRISPR crops

  2018cited by this paper
• Use the patent system to regulate gene editing

  2018cited by this paper
• Discovery of widespread type I and type V CRISPR-Cas inhibitors

  2018cited by this paper
• Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos

  2018cited by this paper
• p53 activation: a checkpoint for precision genome editing?

  2018cited by this paper
• Kinetic basis for DNA target specificity of CRISPR-Cas12a

  2018cited by this paper
• CRISPR plants now subject to tough GM laws in European Union

  2018cited by this paper
• Research on Human Embryos and Reproductive Materials: Revisiting Canadian Law and Policy

  2018cited by this paper
• The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?

  2018cited by this paper
• Novel CRISPR/Cas9 gene drive constructs reveal insights into mechanisms of resistance allele formation and drive efficiency in genetically diverse populations

  2017cited by this paper
• The gene drive bubble: New realities

  2017cited by this paper
• Mind the gaps!

  2017cited by this paper
• Disabling Cas9 by an anti-CRISPR DNA mimic

  2017cited by this paper
• Gene therapy: advances, challenges and perspectives

  2017cited by this paper
• Gene editing using CRISPR/Cas9: implications for dual-use and biosecurity

  2017cited by this paper
• Exploiting off‐targeting in guide‐RNAs for CRISPR systems for simultaneous editing of multiple genes

  2017cited by this paper
• Towards CRISPR/Cas crops - bringing together genomics and genome editing.

  2017cited by this paper
• The creation and selection of mutations resistant to a gene drive over multiple generations in the malaria mosquito

  2017cited by this paper
• Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos

  2017cited by this paper
• Why Gene Editors Like CRISPR/Cas May Be a Game-Changer for Neuroweapons

  2017cited by this paper
• In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease

  2017cited by this paper
• Engineering Quantitative Trait Variation for Crop Improvement by Genome Editing.

  2017cited by this paper
• The De Novo Synthesis of Horsepox Virus: Implications for Biosecurity and Recommendations for Preventing the Reemergence of Smallpox

  2017cited by this paper
• The Patentability of the Crispr-Cas9 Genome Editing Tool

  2017cited by this paper
• Exploring the potential of genome editing CRISPR-Cas9 technology.

  2017cited by this paper
• Anti-CRISPR: discovery, mechanism and function

  2017cited by this paper
• CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein

  2017cited by this paper
• Efficient DNA-free genome editing of bread wheat using CRISPR/Cas9 ribonucleoprotein complexes

  2017cited by this paper
• Knocking out consumer concerns and regulator’s rules: efficient use of CRISPR/Cas ribonucleoprotein complexes for genome editing in cereals

  2017cited by this paper
• Addressing challenges in the clinical applications associated with CRISPR/Cas9 technology and ethical questions to prevent its misuse

  2017cited by this paper
• Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity

  2017cited by this paper
• CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools

  2017cited by this paper
• Inventive steps: the CRISPR patent dispute and scientific progress

  2017cited by this paper
• The commercialization of genome-editing technologies

  2017cited by this paper
• The rise of the ethical license

  2017cited by this paper
• Approaches to Reduce CRISPR Off-Target Effects for Safer Genome Editing

  2017cited by this paper
• Correction of a pathogenic gene mutation in human embryos

  2017cited by this paper
• Unexpected mutations after CRISPR–Cas9 editing in vivo

  2017cited by this paper
• CRISPR, surrogate licensing, and scientific discovery

  2017cited by this paper
• CRISPR/Cas9 and mitochondrial gene replacement therapy: promising techniques and ethical considerations.

  2016cited by this paper
• Canadian regulatory perspectives on genome engineered crops

  2016cited by this paper
• CRISPR/Cas9 in Genome Editing and Beyond.

  2016cited by this paper
• The emerging patent landscape of CRISPR–Cas gene editing technology

  2016cited by this paper
• Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

  2016cited by this paper
• National Academies Hit the Brakes on Gene Drive-Modified Organisms.

  2016cited by this paper
• In vitro and ex vivo strategies for intracellular delivery

  2016cited by this paper
• Induced Pluripotent Stem Cells Meet Genome Editing.

  2016cited by this paper
• UK scientists gain licence to edit genes in human embryos

  2016cited by this paper
• Gene-edited CRISPR mushroom escapes US regulation

  2016cited by this paper
• Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair

  2016cited by this paper
• Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.

  2016cited by this paper
• Non-Mendelian Dominant Maternal Effects Caused by CRISPR/Cas9 Transgenic Components in Drosophila melanogaster

  2016cited by this paper
• Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing

  2016cited by this paper
• CRISPR/Cas9 mediated knockout of the abdominal-A homeotic gene in the global pest, diamondback moth (Plutella xylostella).

  2016cited by this paper
• Ethical Issues in Genome Editing using Crispr/Cas9 System

  2016cited by this paper
• Editing Transgenic DNA Components by Inducible Gene Replacement in Drosophila melanogaster

  2016cited by this paper
• Genome-editing Technologies for Gene and Cell Therapy

  2016cited by this paper
• Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells

  2015cited by this paper
• Opinion: Is CRISPR-based gene drive a biocontrol silver bullet or global conservation threat?

  2015cited by this paper
• Law, history and lessons in the CRISPR patent conflict

  2015cited by this paper
• A CRISPR-Cas9 Gene Drive System Targeting Female Reproduction in the Malaria Mosquito vector Anopheles gambiae

  2015cited by this paper
• Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus.

  2015cited by this paper
• A prudent path forward for genomic engineering and germline gene modification

  2015cited by this paper
• Regulatory framework for gene editing and other new breeding techniques (NBTs) in Argentina.

  2015cited by this paper
• Human, Social, and Environmental Impacts of Human Genetic Engineering

  2015cited by this paper
• Eugenics lurk in the shadow of CRISPR.

  2015cited by this paper
• Safeguarding gene drive experiments in the laboratory

  2015cited by this paper
• Safeguarding CRISPR-Cas9 gene drives in yeast

  2015cited by this paper
• Non-GMO genetically edited crop plants.

  2015cited by this paper
• Rationally engineered Cas9 nucleases with improved specificity

  2015cited by this paper
• Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing

  2015cited by this paper
• DNA-free genome editing in plants with preassembled CRISPR-Cas9 ribonucleoproteins

  2015cited by this paper
• Don’t edit the human germ line

  2015cited by this paper
• Multiple mechanisms for CRISPR–Cas inhibition by anti-CRISPR proteins

  2015cited by this paper
• Ethics of embryo editing divides scientists

  2015cited by this paper
• In vivo genome editing using Staphylococcus aureus Cas9

  2015cited by this paper
• The radical openness of science and innovation

  2015cited by this paper

• Green Drug Discovery: Leveraging Biodiversity for Sustainable Pharmaceutical Solutions

  2026cites this paper
• Hydrogen fuel production from sugarcane and its byproducts – a critical review

  2025cites this paper
• Synthetic biology tools for environmental protection.

  2023cites this paper